P4271 - Effectiveness of A Community-Based Inflammatory Bowel Disease Medical Home Compared to Patients not in a Medical Home

Tuesday, October 29, 2024

10:30 AM – 4:00 PM ET

Location: Exhibit Hall E

Has Audio

Presenting Author(s)

Erica R. Cohen, MD

Director of IBD Chronic Care Program and Research
Capital Digestive Care
Chevy Chase, MD

Erica R. Cohen, MD¹, Timothy E. Ritter, MD², Lucinda J. Van Anglen, BS, PharmD³, Fiza Z. Baloch, BS⁴, Kristin M. Attiogbe, NP¹, Precious A. Anyanwu, PharmD, PhD³, Brooke A. Hodnick, PA-C², Justin G. Kweit, BS¹, Tyler J. Varisco, PharmD, PhD⁵
¹Capital Digestive Care, Chevy Chase, MD; ²GI Alliance, Southlake, TX; ³Healix Infusion Therapy, LLC, Sugar Land, TX; ⁴Anne Burnett Marion School of Medicine at Texas Christian University, Fort Worth, TX; ⁵University of Houston College of Pharmacy, Houston, TX

Introduction: Inflammatory bowel disease (IBD), including both Crohn’s disease (CD) and ulcerative colitis (UC), affects 2.4 million Americans IBD patients have high rates of mental illness, increased risk of comorbid conditions, and a reduced quality of life. Establishment of a multi-disciplinary patient-centered medical home for IBD patients has been shown to improve clinical outcomes and reduce healthcare utilization in academic institutions. However, we lack data evaluating its utility in community practice. Our objective was to assess the efficacy and value of a multidisciplinary IBD home in patients in 2 large private practice IBD home programs compared to control patients receiving standard of care (SOC) management in the community.

Methods: 60 patients were assessed with 30 IBD home patients and 30 case matched controls. Patients were matched for age, sex, diagnosis (CD or UC), disease duration and initiation or change of an advanced therapy. Index data was either the data of entry into the IBD home or initiation/change of the advanced therapy for the case control patients. Data included demographics, disease, and therapy characteristics. Steroid use and preventive health measures were assessed at baseline and 12 months.

Results: 30 IBD home patients were equally matched to SOC control patients as noted in Table 1. Evaluation of the impact of the IBD home versus SOC patients is captured in Figure 1. At 12-months, IBD home patients were significantly more likely to have achieved steroid free remission and less likely to use steroids than controls. IBD home patients were also more likely to be counseled on vaccination and baseline and to have completed recommended vaccines, by 12 month, except for the COVID-19 vaccine. Clinical testing and referrals were also significantly higher in the IBD home group. Almost no behavioral health measures were performed in the SOC control group compared to the IBD home patients (p< 0.0001 in all measures at both timepoints).

Discussion: Establishment of a multi-disciplinary patient-centered medical home for IBD patients is feasible in the community and resulted in improved outcomes including higher steroid free remission rates. Completion of guideline recommended preventive health measures were significantly higher in the IBD home patients. This care model warrants additional study in a larger population with confirmation of long term reduction of IBD disease complications and quality of life.

Figure: Figure 1.

Note: The table for this abstract can be viewed in the ePoster Gallery section of the ACG 2024 ePoster Site or in The American Journal of Gastroenterology's abstract supplement issue, both of which will be available starting October 27, 2024.

Disclosures:

Erica Cohen: Abbvie – Consultant, Speakers Bureau. Eli Lilly & Co – Speakers Bureau. Johnson & Johnson – Consultant, Speakers Bureau. Pfizer – Consultant. Takeda – Speakers Bureau.

Timothy Ritter: AbbVie – Advisory Committee/Board Member, Speakers Bureau. Ardelyx – Advisory Committee/Board Member. Arena Pharmaceuticals – Advisory Committee/Board Member. Boehringer Ingelheim – Advisory Committee/Board Member. Bristol Myers Squibb – Advisory Committee/Board Member, Speakers Bureau. Celgene – Advisory Committee/Board Member. Eli Lilly – Advisory Committee/Board Member, Speakers Bureau. Ferring – Advisory Committee/Board Member. Ferring/Rebiotix – has served on a Data Adjudication Committee. Genentech (Roche) – Advisory Committee/Board Member. Intercept – Advisory Committee/Board Member. Iterative Scopes – Advisory Committee/Board Member, holds shares in Iterative Scopes. Janssen – Advisory Committee/Board Member, Speakers Bureau. Nestlé/Seres – Advisory Committee/Board Member. Pfizer – Advisory Committee/Board Member, Speakers Bureau. Prometheus – Advisory Committee/Board Member. Sanofi – Advisory Committee/Board Member. Takeda – Advisory Committee/Board Member, Speakers Bureau.

Lucinda Van Anglen: Cumberland Pharmaceuticals – Grant/Research Support. Ferring Pharmaceuticals – Grant/Research Support. Novartis Pharmaceuticals – Grant/Research Support. Takeda Pharmaceuticals – Grant/Research Support.

Fiza Baloch indicated no relevant financial relationships.

Kristin Attiogbe: Johnson & Johnson – Advisor or Review Panel Member. Pfizer – Advisor or Review Panel Member.

Precious Anyanwu indicated no relevant financial relationships.

Brooke Hodnick: Abbvie – Consultant. BMS – Consultant. Eli Lilly – Consultant. Johnson & Johnson – Consultant. Takeda – Consultant.

Justin Kweit indicated no relevant financial relationships.

Tyler Varisco indicated no relevant financial relationships.

Erica R. Cohen, MD¹, Timothy E. Ritter, MD², Lucinda J. Van Anglen, BS, PharmD³, Fiza Z. Baloch, BS⁴, Kristin M. Attiogbe, NP¹, Precious A. Anyanwu, PharmD, PhD³, Brooke A. Hodnick, PA-C², Justin G. Kweit, BS¹, Tyler J. Varisco, PharmD, PhD⁵. P4271 - Effectiveness of A Community-Based Inflammatory Bowel Disease Medical Home Compared to Patients not in a Medical Home, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.